// App-Quantinova.ai

FRI0359 : INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS

Researchers

Presenter

  • P. Rahman

Principal Investigators

  • C. T. Ritchlin

  • P. Helliwell

  • W. H. Boehncke

  • P. J. Mease

  • A. B. Gottlieb

  • S. Kafka

  • A. Kollmeier

  • E. C. Hsia

  • X. L. Xu

  • M. Shawi

  • S. Sheng

  • P. Agarwal

  • B. Zhou

  • P. Ramachandran

  • I. Mcinnes

Medical Centers

  • Memorial University of Newfoundland, St. John's, NF, Canada

  • U Rochester Med Ctr, Rochester, United States of America

  • U Leeds, Leeds, United Kingdom

  • Geneva University Hospitals, Geneva, Switzerland

  • Icahn Med School/ Mt Sinai, NY, United States of America

  • Janssen Scientific Affairs, LLC, Raritan, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • Canada

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Janssen and Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved